Since 1992 two new nucleic acid -based tests (Gen-Probe Pace 2 and Abbott LCR) for the diagnosis of Neisseria gonorrhoeae infection have been approved by the U.S. Food and Drug Administration. We systematically assessed the quality of 21 studies that evaluated these tests' performance compared with that of culture for diagnosis of gonorrhea, on the basis of established criteria. We estimated overall test sensitivity and specificity by the testing method, sex, and anatomic site. None of the studies optimally fulfilled all quality criteria; few studies adequately used reference tests or described blinding. The sensitivity and specificity of nucleic acid hybridization (Ç85%, Ç98%) and amplification tests (Ç95%, Ç99%) were high and did not appear to differ substantially by sex or anatomic site. When proficiency in the performance of culture is high, the new tests are comparable to culture and may not offer a substantial advantage; in settings where optimization of culture is difficult, nucleic acid amplification may detect more infections than nucleic acid probe or culture.
Although its incidence has declined substantially in the substantially more expensive. Therefore, choosing a test that offers the best value is no longer a simple task. United States since the 1970s, gonorrhea still causes substantial morbidity [1] . During sexual intercourse, Neisseria gonorrhoeae, the etiologic agent of gonorrhea, may infect mucous See editorial responses by Schachter and Miller on pages membranes of the urethra, endocervix, pharynx, or rectum.
1181 -5 and 1186 -93, respectively. Most women and many men infected with N. gonorrhoeae are asymptomatic [2] .
Complications of infection in women such
After defining terms and briefly describing tests available as pelvic inflammatory disease may result in infertility, ectopic before 1990, this article will focus on the newer technologies pregnancy, and chronic pelvic pain and have the greatest public for detecting N. gonorrhoeae. We address the following queshealth impact.
tions: (1) How does the performance of nucleic acid hybridizaFrom the late 1960s until the late 1980s, options for testing tion or amplification tests compare with that of culture when for gonorrhea were limited. Culture with use of selective methey are used for the presumptive identification of N. gonordium was cheap, highly sensitive, and specific in a proficient rhoeae in endocervical or male urethral specimens? (2) How laboratory and allowed for monitoring of antibiotic resistance, does the performance of amplification tests on urine specimens whereas the performance and cost of alternatives were less compare with that of culture and amplification tests on endoceradvantageous. In the 1990s, the options for diagnostic testing vical or male urethral specimens? (3) Can hybridization and for N. gonorrhoeae significantly expanded with the developamplification tests be used for specimens from nonurogenital ment of nucleic acid detection methods. These methods include sites, e.g., the pharynx or rectum? What is the performance of assays for the presumptive identification of N. gonorrhoeae in amplification tests on vaginal specimens, whether patient-or usual swab specimens, urine assays for N. gonorrhoeae, and clinician-collected? (4) Is the relative performance of hybridcombination assays for the simultaneous detection of N. gonorization or amplification tests affected by the prevalence of inrhoeae and Chlamydia trachomatis in a single swab or urine fection in the population, the presence or absence of symptoms, specimen. These newer tests for detection of gonococcal infecor the sex of the patient? (5) Can these tests be used in pediatric tion offer several important potential advantages but may be populations? (6) What other characteristics influence the use of nonculture tests, from clinical and public health perspectives? lent endocervical or urethral exudate on physical examination are less specific. The sensitivity and specificity of a gram stain for males with urethritis are comparable to those of culture and (2) sexual exposure to a person infected with N. gonorrhoeae. Laboratory test results are generally not available when when used for a ''presumptive'' diagnosis [9, 10] ; for women, the sensitivity of gram staining is much lower. The performance only a suggestive diagnosis is made. A presumptive diagnosis of gonorrhea requires any of the following: (1) typical gramquality of stains of specimens from the rectum, pharynx, conjunctiva, skin, or usually sterile sites such as blood or CSF is negative intracellular diplococci on a gram stain (for men) or in endocervical secretions (for women); (2) growth in cultured generally regarded as suboptimal.
Enzyme immunoassay. This test has better sensitivity for specimens from the urethra (men) or endocervix (women) of an organism presumed to be N. gonorrhoeae, on the basis genital specimens from symptomatic men than for those from women. Because the sensitivity and specificity may be as low of typical colonial morphology, positive oxidase reaction, and typical gram-negative diplococcal morphology; or (3) detection as 87% and 97%, respectively, compared with those of culture (which unacceptably lowers the positive predictive value in of an organism presumed to be N. gonorrhoeae in a nonculture laboratory test (e.g., nucleic acid detection).
populations with low prevalence [11] ) and because costs associated with its use in a low-prevalence population are higher A definitive diagnosis of gonorrhea requires (1) isolation of N. gonorrhoeae from sites of exposure (e.g., urethra, endocerthan those for culture [12] , there are few to no situations for which use of this assay is recommended. vix, throat, or rectum) by culture and demonstration of typical colonial morphology, positive oxidase reaction, and typical Nucleic acid hybridization. Nucleic acid hybridization tests include the Pace 2 and Pace 2C (Gen-Probe, San Diego). Both gram-negative morphology and (2) Chicago, IL) uses nucleic acid amplification to detect a seing by a proficient laboratory, remains the ''gold standard'' for test evaluation, medicolegal purposes, and routine screening quence in the N. gonorrhoeae opa1 gene. The FDA has approved its use on male urethral specimens, endocervical specibecause of its high sensitivity and specificity [4] . In laboratories with good quality control measures, the sensitivity of culture mens, and urine for the detection of gonorrhea. Performance characteristics are reviewed below. may range from 85% to 95% [5, 6] . The retention of the organism for other tests, such as for determination of antimicrobial Nucleic acid amplification: PCR. PCR (Roche Molecular Systems, Branchburg, NJ) also uses nucleic acid amplification susceptibility and subtyping, can be accomplished only with use of culture-based identification. The methods of gonococcal to detect sequences in the N. gonorrhoeae HO1 -HO3 genes.
As of May 1998, it had been submitted but not yet been apculture have been well described [7, 8] . An additional advantage of culture is the low cost per specimen. Disadvantages of proved by the FDA for gonorrhea testing in the United States. culture-based identification include the fastidiousness of the organism, which makes successful growth less likely if isolaMethods tion media, specimen transport, and laboratory technique are not optimal. Multiple steps are necessary for processing speci-
Study Identification
mens, and quality assurance needs to be addressed at each step. Another disadvantage is the length of time necessary from
We used MEDLINE searches of the terms gonorrhea and N. gonorrhoeae to identify studies that evaluated the perforspecimen collection to reporting of results.
Microscopic examination. Microscopic examination of a mance of nucleic acid hybridization and nucleic acid amplification tests from 1992 until October 1997. We examined biblioggram stain (in some settings a methylene blue stain is used) is the only currently available method offering the important raphies of identified studies, and for amplification tests we also examined abstracts published since 1992 from meetings of the advantage of immediate (point-of-care) diagnosis, which facilitates early treatment. We included studies for review if they evaluated the perfor-HIV [13] , and for this review they were applied to subgroups within each study (patients with endocervical, urethral, rectal, mance of two new FDA-approved tests for gonorrhea: a secondgeneration nucleic acid hybridization test (Pace 2 or Pace 2C) or pharyngeal specimens) and a composite score was calculated for each study subgroup. or nucleic acid amplification (LCR or PCR). We excluded studies in which laboratory specimens rather than patient speciIf the sex of the subjects was not identified or there were fewer than five culture-positive subjects, a sample-size score mens were used for the evaluation. When the same authors presented similar data in published study reports and abstracts, was not assigned and performance results were neither abstracted nor combined, unless specimens were taken from the we examined the published study reports for this review. Two authors (E.H.K. and R.E.J.) identified studies independently, pharynx or rectum. We abstracted and present sensitivity and specificity findings for each subgroup in tabular form; we also and a third (J.S.K.) reviewed all identified studies, scores, and extracted data. Review disagreements were resolved by reabstracted sensitivity and specificity data for symptomatic and asymptomatic women and for tests comparing LCR results for review and discussion, and when clarification was necessary, authors were contacted.
specimens from different sites in the same patient. Performance estimates for men may be a combination of results for symptomatic and asymptomatic men, since none of the studies distin-
Study Evaluation
guished between symptomatic and asymptomatic men. The following criteria, adapted from published literature on diagnostic test evaluation [13, 14] , were used to evaluate study Calculation of Sensitivity and Specificity quality: (1) sample size (numbers of both infected and noninfected participants in the study [score of 0 Å 5 or less, 1
Estimates of sensitivity and specificity were first determined with use of culture as the reference criterion for tests comparing Å 6 -25, and 2 Å more than 25]); (2) test quality (whether performance of the evaluated test was described in sufficient endocervical, urethral, and urine specimens. Because culture may miss true-positives, ''false-negatives'' found with a test detail to enable the method to be reproduced, whether the procedure for gonococcal culture was a generally accepted under evaluation may cause the specificity of the other test to be underestimated (misclassification bias). Therefore, many method including the use of selective media and confirmatory testing [abstract descriptions were inadequate for evaluating studies conducted discrepant analysis, consisting of a second test on the specimens positive by the test under evaluation but culture, Pace 2, or LCR quality], and whether the assay included positive and negative controls [score of 0 Å method negative by culture. However, this selective testing introduces another bias [15] . was not described, 1 Å method, including positive and negative controls and selective media, was described, and 2 Å all of Regarding these countervailing biases, a recent study that assumed independence and other analyses that assumed condithe score-1 provisions plus the confirmatory testing used for identification were described]); (3) blinding of investigators to tional dependence of the tests under evaluation (conditions applicable to the evaluation of screening tests to be used for all available test results and clinical information (score of 0 Å no mention of blinding, 1 Å investigators blinded); (4) clinical C. trachomatis or N. gonorrhoeae) both indicate that discrepant analysis improves estimates of specificity ( [16] and T. Green, description (whether description of study participants was complete enough for the reader to ascertain whether the participants unpublished data). Therefore, despite the lack of a reference test on all participants, we abstracted estimates of specificity resembled the reader's clinical population, e.g., factors such as age, sex, risk factors, and symptoms [score of 0 Å no mention based on both culture and discrepant analysis, and estimates of sensitivity based only on culture [16] . The numerator for of source of study participants, 1 Å source of participants noted, 2 Å at least three of the following described: source, the discrepant analysis estimates of specificity included the number negative by both the evaluated test and culture, and demographics, risk factors, and clinical disease/symptoms]); and (5) assembly (whether the spectrum of participants was the denominator included the number negative by culture, less those positive by both the test under evaluation and the referwide enough in terms of risk factors, whether the assembly was described in enough detail to enable a similar sample to ence test. We used the software package StatXact v.3.0 (Cytel, Cambe assembled by another investigator, and whether the reference test was applied independently of the results of the test bridge, MA) to calculate 95% confidence intervals of sensitivity and discrepant analysis -based specificity for tests on endocerunder evaluation [score of 0 Å no mention of participant assembly, 1 Å assembly described]).
vical, urethral, and urine specimens [17] . Since the resulting estimates were similar, we calculated combined estimates of An additional criterion was the consistent application of a reference test to the diseased and nondiseased populations.
these subgroups by summing the numerators and denominators across studies. This standard method of combining results Since none of the studies applied a reference test to all partici-/ 9c5b$$no36
10-14-98 10:34:58 cidas UC: CID weighs each study by the number of its participants and yields women were identified in three studies evaluating nucleic acid hybridization; the combined sensitivity and discrepant analyunbiased estimates with minimum variance, under the assumption of homogeneity of results across studies [18] .
sis -based specificity for these women were 94.6% and 99. . In women and men, the combined sensitivities were greater study quality are shown in table 1 [19 -39] . The maximum than 95% and the combined specificities after discrepant analyachievable total score was 12; no study optimally fulfilled all sis exceeded 99.5%. criteria, and two studies attained the highest score that we assigned, a 6 [33, 34] . Only 3 study reports partially described
Comparison of Urine Nucleic Acid Amplification with Urethral participant assembly, 1 study report gave a full clinical descripor Cervical Culture tion of participants [35] , and only 4 study reports indicated
Only LCR is FDA-approved for the detection of N. gonorthat investigators were blinded [22, 31, 33, 34] . Eight of 9 rhoeae in urine. With use of gonococcal culture as the gold studies involving men and 7 of 17 studies involving women standard, LCR was highly sensitive for women and men (table had more than 25 culture-positive subjects [13] . Most studies 4). The combined estimate for discrepant analysis -based speci- (17) settings. None of the reports of studies involving men or using For this comparison the gold standard differs from the above amplification tests described the symptoms of participants.
comparisons; specimens in which gonorrhea was identified by Prevalence ranged from 0.6% to 19.3% in women and 5.9%
LCR and confirmed by culture or pilin were considered trueto 55.7% in men.
positives. Specimens negative by LCR, if also negative by For discrepant analysis all the studies comparing hybridizaculture or pilin, were considered true-negatives. For women tion (Pace 2) to culture for diagnosis of gonorrhea used a probe (n Å 508), LCR testing of urine specimens had a sensitivity competition assay; both tests target the same gene sequence.
of 52.4% in one study [37] and 100% in another [36] (73.0% The studies comparing amplification (LCR) to culture used a combined); combined specificity was 99.6%. The combined second amplification test targeting a nucleotide sequence in the estimates of sensitivity and specificity for men (n Å 200) were pilin gene, a different DNA sequence than that used in the 95.5% and 100%, respectively [36, 37] . LCR test.
Comparison of Vaginal Nucleic Acid Amplification with Comparison of Endocervical and Urethral Nucleic Acid Cervical Nucleic Acid Amplification Hybridization or Amplification with Endocervical and Urethral
One study compared LCR performance with use of providerCulture obtained endocervical specimens and patient-obtained vaginal The culture-based sensitivity, specificity, discrepant analyspecimens [35] ; this use of LCR has not been FDA-approved. sis -based specificity, and combined results are presented for
The sensitivity of LCR on patient-obtained vaginal specimens endocervical (table 2) and urethral (table 3) specimens for each was 100%, and the specificity after discrepant analysis was of the studies that evaluated the performance of nucleic acid 99.6%. LCR of vaginal specimens was positive for 53 women, hybridization (Pace 2) and nucleic acid amplification (LCR).
and culture of cervical specimens detected 44 infections. One Because of the small sample size and small number of positives additional study has evaluated the acceptability and usefulness in each of the studies, the confidence intervals for individual of vaginal washes in premenarchal girls by means of PCR and studies are wide.
culture; PCR detected two vaginal gonococcal infections, while Nucleic acid hybridization. Women in high-prevalence setculture using a traditional swab specimen detected one [40] . tings and 304 symptomatic women were identified in seven studies evaluating nucleic acid hybridization; the combined
Comparison of Rectal Nucleic Acid Detection with Culture
sensitivity and discrepant analysis -based specificity for these women were 93.1% and 98.6%, respectively [19, 22 -26, 32] .
Nucleic acid hybridization. The combined sensitivity of Pace 2 in rectal specimens in three studies was 96.4% [25, 29, Women in low-prevalence settings and 56 asymptomatic / 9c5b$$no36 10-14-98 10:34:58 cidas UC: CID Total: 100 (8) ML 2 0 1 0 Not scored NOTE. Pace 2 Å Gen-Probe, San Diego; LCR-ligase chain reaction, Abbott, North Chicago, IL. * Sample size refers to whether the numbers of infected and noninfected participants in the study were more than 5 (scores: 0 Å 5 or less, 1 Å 6 -25, and 2 Å more than 25 positive for infection).
† ML Å Martin Lewis; MNYC Å modified New York City; MTM Å modified Thayer Martin; NYC Å New York City; TM Å Thayer Martin. ‡ Test quality refers to whether the performance of the evaluated test and culture was described in sufficient detail to enable the methods to be reproduced and whether the assay included positive and negative controls. Included in this criterion was whether the procedure for gonorrheal culture was a generally accepted method including the use of selective media and confirmatory testing (the abstract descriptions were inadequate to evaluate culture, Pace 2, or LCR quality). Scores: 0 Å method not described; 1 Å method, including positive and negative controls and selective media, was described; 2 Å method, positive and negative controls, selective media, and confirmatory testing used for identification were all described.
§ Blinding refers to whether during testing the investigators were blinded to all available test results and clinical information (scores: 0 Å no mention of blinding; 1 Å investigators blinded with regard to the test under evaluation; 2 Å investigators blinded with regard to both the test under evaluation and the tiebreaker test).
x Clinical description refers to whether a description of the study participants was complete enough for the reader to ascertain whether the participants resembled the reader's clinical population, including with regard to factors such as age, sex, risk factors, and symptoms (scores: 0 Å no mention of source of study participants; 1 Å source of study participants noted; 2 Å at least three of the following are described: source, demographics, risk factors, and clinical disease of study participants).
# Assembly refers to whether the spectrum of participants was wide enough in terms of risk factors and whether the assembly was described in enough detail to allow a similar sample to be assembled by another investigator (scores: 0 Å no mention of participant assembly or results of first test used to determine which participants underwent the reference test (discrepant analysis); 1 Å participant assembly incompletely described; 2 Å wide spectrum and detailed description of assembly).
** Quality-of-evidence score also includes the criterion of application of a reference test, which refers to whether another reference test was applied consistently to the diseased and nondiseased populations (scores: 2 Å the appropriate test was applied to all participants; 1 Å different reference tests were used among the participants; 0 Å a reference test not used on all participants [all studies scored 0]).
/ 9c5b$$no36
10-14-98 10:34:58 cidas UC: CID 30]. Combined discrepant analysis -based specificity in two of specimen was positive by culture or by LCR (a result confirmed by pilin, e.g., discrepant analysis), LCR detected N. gonorthe three studies was 100% [29, 30] ; this use of Pace 2 has not been FDA-approved. The sample sizes were small and the rhoeae in the rectum in 10 of 22 women and 6 of 47 men, while culture did not detect any infections [36] . number positive in each study was less than 20.
Nucleic acid amplification. The use of LCR or PCR for
Comparison of Pharyngeal Nucleic Acid Detection with Culture
the detection of gonorrhea in rectal specimens has been evaluated in one published study but has not been FDA-approved. Nucleic acid hybridization. The combined sensitivity of Pace 2 for detection of gonorrhea in pharyngeal specimens was In a subsample of women and men for whom a urogenital Table 3 . Sensitivity and specificity of nucleic acid hybridization (Pace 2) and nucleic acid amplification (LCR) to detect gonococcal infections of the male urethra. 77.4% [25, 29, 30 ]. This sensitivity is at the lower end of a clude the quality of the studies, the relative sensitivity and specificity of the tests, research issues, and public health implicommon estimate for culture sensitivity [5, 6] . After discrepant analysis, combined specificity was 99.9% [29, 30] ; this use of cations. Pace 2 has not been FDA-approved.
Nucleic acid amplification. The use of amplification for
Study Quality Evaluation
the detection of gonorrhea in pharyngeal specimens has been We applied published criteria to evaluate the quality of studevaluated in one published study. In a subsample of women ies [14] that we identified. The limited degree to which studies and men for whom a urogenital specimen was positive by met these criteria deserves special emphasis. Publication bias culture or by LCR (a result confirmed by pilin, e.g., discrepant may also have played a role in which studies were published, analysis), LCR detected N. gonorrhoeae in the pharynx of 4 although we do not know in which direction any publication of 22 women and 6 of 47 men, while culture detected infection bias would influence either study quality or estimates of test in 1 woman and 2 men [36] ; this use of LCR has not been performance. Given the continued high incidence of gonococ-FDA-approved.
cal infections and the millions of gonococcal tests performed in the United States each year (S. DeLisle, personal communi- Both study-specific and summary estimates of sensitivity study populations, prevalence was above 5%. Performance of and specificity are uncertain for a number of reasons. The use the hybridization or amplification test did not appear to change of culture as a reference standard is susceptible to poor quality with prevalence of infection above 5%. There were few studies control. In laboratories with good quality-control measures, the with prevalence of infection below 5%. In women tested with sensitivity of culture may range from 85% to 95% [5, 6] , and Pace 2, the presence of symptoms did not appear to affect test in the studies reviewed here, culture procedures and confirmaperformance. However, no studies have evaluated the influence tory tests differed greatly. A second difficulty relates to the use of symptoms on amplification test performance in women with of discrepant analysis as an analytic tool; procedures used for endocervicitis or in men tested by either hybridization or amplidiscrepant analysis (probe competition assay, pilin) have not fication. In these reviewed studies, the sex of the patient did themselves been evaluated in published studies and are not not appear to affect the performance of either test.
used uniformly. Yet, in most of the studies mentioned in this review, these tests served as tie-breaker tests when the results of Discussion culture differed from the results of the assay under evaluation. rectal specimens, and LCR detected more positives than culture in endocervical or urethral specimens, but more studies with in one study [36] . The use of amplification tests on extragenital larger sample sizes are needed.
specimens needs further evaluation, although their use on proIn settings where prevalence is low or tests are used for vider-collected or patient-collected vaginal specimens shows screening, the specificity of a test may be more important. The promise. specificity of Pace 2 appears to be nearly 99%, and that of LCR exceeds 99.5% if estimates are based on discrepancy analysis (probe competition assay or pilin) ( [16] and T. Green, Summary and Public Health Implications personal communication). This difference translates into 98 false-positives with Pace 2, compared with 49 false-positives
The results of the review suggest that nucleic acid hybridization and amplification offer high-performance alternatives to with LCR, in a hypothetical population of 10,000 with a prevalence of 2%; a small change in specificity has a large impact gonococcal culture. Conversely, culture remains an excellent test for the diagnosis of gonorrhea in comparison with newer on false-positives. Estimates of specificity may vary between studies, for reasons similar to those for sensitivity. The specitests. Whereas a variety of tests for gonorrhea can be used to detect N. gonorrhoeae in various anatomic sites, only culture ficity of amplification appears to be similar for urine, endocervical, and urethral specimens.
can be used for isolation of the agent for antimicrobial testing and retention for medicolegal purposes. The widespread use Unresolved issues include whether Pace 2 is actually less specific than LCR. Discrepant analysis for LCR uses nucleic of nonculture tests for the diagnosis of gonorrhea has resulted in fewer gonococcal isolates available for antimicrobial testing. acid amplification, which may be more sensitive and specific than the probe competition assay used in discrepant analysis Lack of routine antimicrobial susceptibility testing may interfere with clinicians' and public health practitioners' abilities to for Pace 2. A second issue is that the performance of other amplification or hybridization tests awaiting approval or in detect and respond promptly to the emergence of antimicrobialresistant N. gonorrhoeae. 
